Download PDF
Thromb Haemost 1979; 42(02): 621-625
DOI: 10.1055/s-0038-1666900
Original Article
Schattauer GmbH Stuttgart

Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone

G G Nenci
The Medical Clinic, University of Perugia, Perugia, Italy
,
G Agnelli
The Medical Clinic, University of Perugia, Perugia, Italy
,
M Berrettini
The Medical Clinic, University of Perugia, Perugia, Italy
,
P Parise
The Medical Clinic, University of Perugia, Perugia, Italy
,
E Ballatori
The Medical Clinic, University of Perugia, Perugia, Italy
› Author Affiliations
Further Information

Publication History

Received 30 June 1978

Accepted 05 October 1978

Publication Date:
23 August 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.

 

  • References

  • 1 Ali M, McDonald JW D. 1975; Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. Journal of Laboratory and Clinical Medicine 89: 868
    PubMedGoogle Scholar
  • 2 The Anturane Reinfarction Trial Research Group. 1978; Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of Medicine 298: 289
    CrossrefPubMedGoogle Scholar
  • 3 Ballatori E, Nenci GG. 1975. Piano degli esperimenti per il controllo dell'efficacia di farmaci antiaggreganti piastrinici nella prevenzione della recidiva della trombosi arteriosa. In Proceedings of the 28th Scientific Session, Italian Society of Statistics; Padova: 1975. p 17-31
    Google Scholar
  • 4 Blakely JA, Gent M. 1975. Platelets, drugs and longevity in a geriatric population. In Hirsh J, Cade JF, Gallus AS. et al. (eds.) Platelets, Drugs and Thrombosis. S. Karger; Basel: pp 284-291
    Google Scholar
  • 5 Breddin K, Hoff F. 1968. Die Thrombozytenfunktion bei hämorrhagischen Diathesen. Thrombosen und Gefäßkrankheiten. F. K. Schattauer-Verlag; Stuttgart - New York:
    Google Scholar
  • 6 Breddin K, Krzywanek HJ, Bald M, Kutschera J. 1974. Is enhanced platelet aggregation a risk factor for thromboembolic complications in atherosclerosis. In Caprino L, Rossi EC. (eds.) Platelet Aggregation and Drugs. Academic Press; London: pp 197-212
    Google Scholar
  • 7 Breddin K, Krzywanek HJ, Ziemen J, Bauer H, Grün H. 1977. Enhanced platelet aggregation as a risk factor for progress and complications of vascular disease. New findings with a platelet aggregation test (PAT III) and on the dependence of different aggregation tests on morphologic platelet changes In Agnoli A, Fazio C. (eds.) Platelet Aggregation in the Pathogenesis of Cerebrovascular Disorders. Springer-Verlag; Heidelberg and New York: pp 44-62
    Google Scholar
  • 8 Buchanan M, Hirsh J. 1975; Comparison of in vivo and in vitro effects of platelet function suppressing drugs. Thrombosis et Diathesis Haemorrhagica 34: 552
    PubMedGoogle Scholar
  • 9 Cortellaro M, Fassio G, Deambrogi L, Polli EE. 10.05.1977. Sulfinpyrazone in coronary heart disease. The Anturan Reinfarction Italian Study (ARIS). In Abstracts of the First Florence Conference on Haemostasis and Thrombosis. Florence: p 180
    Google Scholar
  • 10 De Gaetano G. 1975; Pharmacological properties of drugs inhibiting platelet aggregation. Acta Clin. Belg 30: 184
    CrossrefPubMedGoogle Scholar
  • 11 Essien EM, Mustard JF. 1977; Inhibition of platelet adhesion to rabbit aorta by sulfinpyrazone and acetylsalicylic acid. Atherosclerosis 27: 89
    CrossrefPubMedGoogle Scholar
  • 12 Evans G. 1972; Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia. Surgery Forum 23: 239
    PubMedGoogle Scholar
  • 13 Fleming JS, Buyniski JR. 1977; Enhanced platelet aggregability in dogs following myocardial infarction. Life Sciences 20: 843
    CrossrefPubMedGoogle Scholar
  • 14 Gent M. 1975. Canadian cooperative study of recent recurrent presumed cerebral emboli (RRPCE): Design and organization of the study. In Hirsh J, Cade JF, Gallus AS. et al. (eds.) Platelets, Drugs and Thrombosis. S. Karger; Basel: pp 253-257
    Google Scholar
  • 15 Mustard JF, Packham MA. 1975; Platelets, thrombosis and drugs. Drugs 9: 19
    CrossrefPubMedGoogle Scholar
  • 16 Packham MA, Mustard JF. 1977; Clinical pharmacology of platelets. Blood 50: 555
    PubMedGoogle Scholar
  • 17 Rosenberg JC, Sell T. 1975; Platelet release and aggregation induced by antithymocyte globulin: in vitro effects of inhibitors. Transplantation 20: 346
    CrossrefPubMedGoogle Scholar
  • 18 Siegel S. 1956. Non Parametric Statistics. McGraw Hill-Kögakusha; Tokyo:
    Google Scholar
  • 19 Steele P, Battock D, Genton E. 1975; Effect of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Circulation 52: 473
    CrossrefPubMedGoogle Scholar
  • 20 Steele P, Carroll J, Overfield D, Genton E. 1977; Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks. Stroke 8: 396
    CrossrefPubMedGoogle Scholar